Equities analysts expect United Therapeutics Co. (NASDAQ:UTHR) to announce earnings of $2.31 per share for the current quarter, according to Zacks. Five analysts have made estimates for United Therapeutics’ earnings, with the highest EPS estimate coming in at $3.13 and the lowest estimate coming in at $1.88. United Therapeutics posted earnings of $3.98 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 42%. The business is scheduled to report its next quarterly earnings report on Wednesday, October 30th.
On average, analysts expect that United Therapeutics will report full year earnings of ($1.96) per share for the current financial year, with EPS estimates ranging from ($3.73) to ($0.50). For the next fiscal year, analysts expect that the firm will post earnings of $9.36 per share, with EPS estimates ranging from $7.62 to $11.74. Zacks’ earnings per share averages are an average based on a survey of analysts that that provide coverage for United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $4.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.40 by $2.26. The firm had revenue of $373.60 million during the quarter, compared to analysts’ expectations of $331.78 million. United Therapeutics had a negative return on equity of 4.54% and a negative net margin of 7.69%.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Amundi Pioneer Asset Management Inc. increased its holdings in shares of United Therapeutics by 18.8% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 76,221 shares of the biotechnology company’s stock valued at $8,945,000 after purchasing an additional 12,087 shares during the period. Denali Advisors LLC grew its holdings in United Therapeutics by 31.9% during the second quarter. Denali Advisors LLC now owns 86,500 shares of the biotechnology company’s stock worth $6,752,000 after acquiring an additional 20,900 shares during the period. WINTON GROUP Ltd grew its holdings in United Therapeutics by 10.7% during the second quarter. WINTON GROUP Ltd now owns 192,075 shares of the biotechnology company’s stock worth $14,993,000 after acquiring an additional 18,559 shares during the period. Empowered Funds LLC grew its holdings in United Therapeutics by 13.8% during the second quarter. Empowered Funds LLC now owns 24,960 shares of the biotechnology company’s stock worth $1,948,000 after acquiring an additional 3,023 shares during the period. Finally, Unigestion Holding SA acquired a new position in United Therapeutics during the second quarter worth $771,000. Institutional investors own 94.37% of the company’s stock.
UTHR traded up $0.25 during trading on Friday, reaching $81.92. 3,921 shares of the stock traded hands, compared to its average volume of 481,184. The stock has a market cap of $3.57 billion, a price-to-earnings ratio of 6.12 and a beta of 0.95. United Therapeutics has a fifty-two week low of $74.31 and a fifty-two week high of $128.94. The company has a debt-to-equity ratio of 0.31, a current ratio of 4.62 and a quick ratio of 4.41. The stock’s 50-day simple moving average is $81.73 and its two-hundred day simple moving average is $86.64.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Recommended Story: What are earnings reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.